National Planning Corporation’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-45,841
Closed -$4.07M 51
2017
Q3
$4.07M Sell
45,841
-4,547
-9% -$346K 0.34% 60
2017
Q2
$3.65M Buy
50,388
+2,754
+6% +$185K 0.28% 78
2017
Q1
$3.1M Buy
47,634
+2,766
+6% +$174K 0.23% 94
2016
Q4
$2.73M Sell
44,868
-1,790
-4% -$109K 0.21% 100
2016
Q3
$2.75M Sell
46,658
-2,273
-5% -$147K 0.22% 100
2016
Q2
$3.27M Buy
48,931
+6,220
+15% +$379K 0.25% 89
2016
Q1
$2.67M Sell
42,711
-3,487
-8% -$194K 0.23% 95
2015
Q4
$2.45M Buy
46,198
+5,890
+15% +$339K 0.2% 113
2015
Q3
$2.57M Sell
40,308
-605
-1% -$39.4K 0.24% 90
2015
Q2
$2.79M Buy
40,913
+6,236
+18% +$407K 0.25% 88
2015
Q1
$2.21M Sell
34,677
-1,714
-5% -$104K 0.2% 110
2014
Q4
$2.44M Buy
36,391
+1,818
+5% +$115K 0.17% 113
2014
Q3
$2.03M Buy
34,573
+355
+1% +$19.7K 0.15% 124
2014
Q2
$1.93M Buy
34,218
+2,261
+7% +$119K 0.15% 139
2014
Q1
$1.71M Buy
31,957
+1,369
+4% +$69.2K 0.15% 144
2013
Q4
$1.61M Buy
30,588
+1,923
+7% +$94.5K 0.14% 157
2013
Q3
$1.32M Buy
28,665
+4,830
+20% +$214K 0.13% 173
2013
Q2
$977K Buy
+23,835
New +$1.04M 0.12% 182

Other funds holding ABBV

National Planning Corporation's ABBV Position: Q4 2017 in Review

National Planning Corporation sold out of AbbVie (ABBV) in Q4 2017, closing a stake of 45,841 shares — an estimated $4.07M sold.

National Planning Corporation first reported a position in ABBV in Q2 2013 and held it in 18 quarters. The position peaked at $4.07M in Q3 2017. 2,000 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

  • National Planning Corporation reported no remaining AbbVie position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 45,841 AbbVie shares in Q4 2017, an estimated $4.07M.
  • National Planning Corporation first reported a position in AbbVie in Q2 2013 and held it in 18 quarters.
  • National Planning Corporation's AbbVie position peaked at $4.07M in Q3 2017.
  • 2,000 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.